News

FDA approves expanded use of Moderna’s RSV shot, but uncertainty remains
The Food and Drug Administration (FDA) expanded the approval of Moderna’s RSV vaccine late Thursday to include people 18 to ...
kffhealthnews1d
Moderna Says Its RSV Vaccine Effectively Protects Older Adults
Moderna announced that its experimental shot was nearly 84 percent effective at preventing respiratory syncytial virus symptoms in a large study of adults 60 years and older. The drugmaker plans to ...
Celebrated, then disparaged: mRNA’s promise is tarnished under Trump
The promise of mRNA technology seemed boundless after the success of the coronavirus vaccines, but Robert F. Kennedy Jr. has ...
WATE 6 On Your Side on MSN1d
What to know about COVID vaccines for children, pregnant women after RFK Jr.’s change
Public health and infectious disease experts said they were surprised and confused about the move, and questioned why the HHS did not offer any reasoning for its decision.
FDA clears Moderna’s RSV vaccine for use in people ages 18 to 59
The Food and Drug Administration expanded the approval of Moderna’s RSV vaccine on Thursday, extending the license to include ...
FDA expands approval of Moderna's RSV vaccine to some adults under age 60
The FDA expanded its approval of Moderna's RSV vaccine on Thursday to include adults under age 60 at increased risk of the ...
Moderna falls on doubts over new CDC panel's backing of RSV vaccine
The mRNA-based RSV shot, mRESVIA, secured U.S. approval on Thursday for use in at-risk adults aged 18 to 59 years, but needs ...
Moderna falls on fears new CDC vaccine advisory panel could cloud RSV shot prospects
Moderna's shares fell 2.5% before the bell on Friday, on concerns whether a new CDC advisory panel would back the use of the ...
Moderna wins FDA OK to widen use of RSV vaccine
The agency’s decision to clear Moderna’s shot for use in certain younger adults is a much-needed win for a company that’s ...
FDA expands Moderna's RSV vaccine approval to at-risk adults
The U.S. Food and Drug Administration has approved Moderna’s (MRNA) RSV vaccine, mRESVIA (mRNA-1345), for preventing lower respiratory tract disease in adults aged 18 to 59 ...
Moderna Receives U.S. FDA Approval for RSV Vaccine, mRESVIA, in Adults Aged 18–59 at Increased Risk for RSV Disease
Expanded indication builds on existing U.S. FDA approval of mRESVIA for adults aged 60 and older CAMBRIDGE, MA / ACCESS ...
EconoTimes2d
FDA Expands Moderna’s RSV Vaccine Use to At-Risk Adults Aged 18–59
The U.S. Food and Drug Administration (FDA) has expanded the use of Modernas (NASDAQ:MRNA) RSV vaccine, mRESVIA, to adults ...